EUVIMEDEUVIMED entdecken
Open Access

Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke

Ori S Cohen, Manisha Sinha, Yongting Wang iD, Tyler Daman iD, Pi-Chun Li, Catherine Deatherage, Berenice Charrez iD, Anish Deshpande, Samuel Jordan, Nyasha J Makoni iD, Katie LeDonne, Christopher J Dale und 9 weitere

Stroke · 2025

DOI: 10.1161/strokeaha.124.049908 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Stroke, 2025. Verfasst von Ori S Cohen und 20 weiteren Autor:innen. Beteiligte Einrichtung: Elevian, Inc, Research and Development, Newton, MA (O.S.C., M.S., Y.W., T.D., P.-C.L., C.D., B.C., A.D., S.J., N.J.M., K.L.D., C.J.D., M.A., A.S.). Hauptthemen laut MEDLINE: Growth Differentiation Factors, Recovery of Function, Bone Morphogenetic Proteins, Stroke. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Stroke remains a leading cause of death and disability, underscoring the urgent need for treatments that enhance recovery. GDF11 (growth differentiation factor 11), a member of the TGF-β (transforming growth factor-β) superfamily, is a circulating protein involved in cellular development and tissue repair. GDF11 has gained attention for its potential regenerative properties in aging and disease contexts, making it a candidate for stroke recovery therapies. METHODS: The therapeutic benefits of rGDF11 (recombinant GDF11) were evaluated using a rat ischemic stroke model, in which focal cerebral infarcts were induced in 8- to 10-week-old young adult male Sprague-Dawley rats by permanently occluding the proximal right middle cerebral artery. Rats received single or multiple doses of rGDF11 (0.1–4 mg/kg) or vehicle from 24 to 72 hours post-injury. Sensorimotor functions were evaluated, and brain and serum samples were examined to determine the mechanisms of action and identify biomarkers, using immunofluorescence, target-specific ELISAs, and an aptamer-based proteomics platform. RESULTS: We confirmed rGDF11 activity in vitro and in established in vivo mouse models of cardiac hypertrophy and glucose metabolism and assessed the efficacy of rGDF11 treatment in 6 preclinical stroke studies using independent Contract Research Organizations, with all study animals and treatment groups blinded. All 6 studies revealed consistent improvement in sensorimotor outcomes with rGDF11. rGDF11-treated rats showed increased cortical vascularization and radial glia in the ventricular zone. Serum analysis revealed that rGDF11 caused dose-dependent decreases in CRP (C-reactive protein) and identified novel pharmacodynamic biomarkers and pathways associated with potential mechanisms of action of rGDF11. CONCLUSIONS: These results demonstrate that systemically delivered rGDF11 enhances neovascularization, reduces inflammation, promotes neurogenesis, and improves sensorimotor function post-injury in a rat model of ischemic stroke. More importantly, these data define an optimized and clinically feasible rGDF11 dosing regimen for therapeutic development in ischemic stroke and identify a panel of candidate pharmacodynamic and mechanistic biomarkers to support clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Growth Differentiation FactorsRecovery of FunctionBone Morphogenetic ProteinsStrokeIschemic StrokeBrain IschemiaAnimalsRats, Sprague-DawleyRatsMaleDisease Models, AnimalRecombinant Proteins

Stichwörter der Autor:innen

agingbiomarkersglucoseinflammationstroke

Substanzen

Growth Differentiation FactorsGdf11 protein, ratRecombinant ProteinsBone Morphogenetic Proteins

Autor:innen und Institutionen

  • Elevian, Inc, Research and Development, Newton, MA (O.S.C., M.S., Y.W., T.D., P.-C.L., C.D., B.C., A.D., S.J., N.J.M., K.L.D., C.J.D., M.A., A.S.).
  • Alevian, Inc, Research and Development, Lexington, MA (O.S.C., A.S.).
  • Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA (L.B.D., C.P., C.G., A.J.W., L.L.R., R.T.L.).
  • Department of Neurology, Harvard Medical School, Massachusetts General Hospital, Boston (S.P.F.).

ORCID-Profile: Yongting Wang, Tyler Daman, Berenice Charrez, Nyasha J Makoni, Cheryl Pan, Caterina Gasperini, Amy J Wagers, Lee L Rubin, Seth P Finklestein, Richard T Lee, Anthony Sandrasagra

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Cohen, O. S., Sinha, M., Wang, Y., Daman, T., Li, P. C., Deatherage, C., Charrez, B., Deshpande, A., Jordan, S., Makoni, N. J., LeDonne, K., Dale, C. J., Ben Driss, L., Pan, C., Gasperini, C., Wagers, A. J., Rubin, L. L., Finklestein, S. P., Allen, M., …, & Sandrasagra, A. (2025). Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke. Stroke. https://doi.org/10.1161/strokeaha.124.049908

Vancouver

Cohen OS, Sinha M, Wang Y, Daman T, Li PC, Deatherage C, et al. Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke. Stroke. 2025. doi:10.1161/strokeaha.124.049908

BibTeX
@article{Cohen2025,
  author = {Cohen, Ori S and Sinha, Manisha and Wang, Yongting and Daman, Tyler and Li, Pi-Chun and Deatherage, Catherine and Charrez, Berenice and Deshpande, Anish and Jordan, Samuel and Makoni, Nyasha J and LeDonne, Katie and Dale, Christopher J and Ben Driss, Laura and Pan, Cheryl and Gasperini, Caterina and Wagers, Amy J and Rubin, Lee L and Finklestein, Seth P and Allen, Mark and Lee, Richard T and Sandrasagra, Anthony},
  title = {Recombinant GDF11 Promotes Recovery in a Rat Permanent Ischemia Model of Subacute Stroke},
  journal = {Stroke},
  year = {2025},
  doi = {10.1161/strokeaha.124.049908}
}
Kostenlos starten →